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Abstract
Autoimmune polyglandular syndrome, type 1 (APS-1) is a rare syndrome. Here
we present a case report of a 24-year-old female patient who complained of
progressive weakness. While autoimmune hepatitis was diagnosed, no
improvement of biochemical parameters was obtained after immunosuppressive
treatment. Hypoparathyroidism and adrenocortical failure were identified. Her
health status clearly improved once proper control of the calcium-phosphate
metabolism was obtained and after the administration of substitution
hydrocortisone doses, leading to full normalization of biochemical liver tests.
The reported case illustrates a rare form of APS-1 failure, in which the diagnosed
autoimmune hepatitis was only the first symptom.
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Introduction
Autoimmune polyglandular syndrome, type 1 (APS-1, also known as
Whitaker’s syndrome, Blizzard’s syndrome and autoimmune polyglandular-
candidiasis-ectodermal dystrophy syndrome – APECEDS) is a rare syndrome
of autoimmune, multi-organ disorders, together with blastomycosis and
ectodermal dystrophy [1, 2]. Autoimmune polyglandular syndrome, type 1
results from mutations in the autoimmune regulator gene (AIRE) at locus
21q22.3, which encodes a 54-kDa protein that is present in the epithelial
cells of the thymus core and participates in control of central and peripheral
immunological tolerance [3, 4]. The diagnosis of APS-1 is based on
identification of, at least two, out of the three, most frequently observed
components of the syndrome (recurring candidosis, hypoparathyroidism,
and adrenal cortex failure); however, other components may also occur,
including type 1 diabetes mellitus, hypergonadotropic hypogonadism,
vitiligo, and alopecia areata [5]. The clinical picture may include diarrhoea,
symptoms of poor absorption resulting from the atrophy of endocrine cells
in the gastric tract and dysfunction of parietal cells that may lead to
pernicious anaemia. Additional symptoms may include enamel hypoplasia,
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nail dystrophy, tympanic membrane sclerosis, and
acquired leukoderma. In some patients, congenital
asplenia, cholelithiasis (likely resulting from
absorption disorders), or autoimmune hepatitis may
be observed.
Case report
A 24-year-old non-smoking woman was
admitted to the Department of Infectious
Diseases, Medical University of Lodz, Poland, for
progressive weakness and elevated amino  -
transferase activities that persisted over 3 months:
ALT up to 300 U/l and AST up to 250 U/l.
The patient’s history included cholecystectomy,
performed 2 years before for cholelithiasis and
subcapsular cataract surgery in the right eye with
artificial lens implantation (surgery date not
available). Recurring candidosis of the oral cavity
and hypoparathyroidism had been observed since
the patient’s early childhood. Unfortunately, the
patient had not been covered by continuous
endocrine care. The patient used nystatin in topical
applications for the recurring candidosis; however,
the patient did not receive calcium, vitamin D, or
its metabolites for hypoparathyroidism. She did not
receive any other medications, and she had never
consumed alcohol. She regularly menstru  ated, did
not use any hormonal contraception, and was not
pregnant.
No deviations from normal status were found in
the medical examination performed upon admis  -
sion. Abdominal sonography revealed a normal-
sized liver with uniform echostructure, a typical
post-cholecystectomy status. Laboratory blood
serum tests provided the following results: ALT 508
U/l, AST 324 U/l, activity of γ-glutamyl-trans  -
peptidase 15 U/l, alkaline phosphatase 197 U/l, total
bilirubin concentration 1.55 mg/dl, total protein 
8.51 g/dl, and γ-globulin 30% (2.55 g/dl). Blood cell
count, electrolytes, urea, and creatinine test results
were all within normal values.
Antinuclear antibodies were identified at 
113.8 IU/ml (N > 23 positive result). No other
antibodies were detected, including anti-
mitochondrial antibodies, type 1 liver and kidney
anti-microsomal antibodies, anti-soluble liver
antigen antibodies, and anti-liver cytosol antibodies.
Hepatitis A, B, and C viruses, as well as Wilson’s
disease, were excluded.
High aminotransferase activities were observed
during hospitalization. After 3 months, high activities
of ALT (353 U/l) and AST (230 U/l) persisted, while
measured thyroid-stimulating hormone, FT3, and FT4
concentrations were within normal values.
Histopathology of a collected liver section revealed
chronic hepatitis of moderate activity with
inflammatory infiltrations of lymphoid and plasmatic
cells and with periportal and bridging porto-portal
fibrosis. This microscopic image corresponded to
autoimmune hepatitis (Figures 1 A, 1 B).
Type 1 autoimmune hepatitis was diagnosed in
the patient (the value of the Autoimmune Hepatitis
Scoring System was 17), prompting the admi  -
nistration of immunosuppressive therapy (predni  -
solone 30 mg/day). Improvements, such as decre  -
ased ALT (116 U/l) and AST (69 U/l), were achieved,
as was a reduction in γ-globulins (1.7 g/dl). Azathio  -
prine was then added at a dose of 100 mg/day, with
the prednisolone dose reduced to 5 mg/day. After 
2 months of the therapy, repeated rises in ALT values
were noted (up to 211 U/l) and in AST values 
(up to 86 U/l). During a subsequent hospitalisation,
tetany attack occurred in the patient for the first time
in her life, with no deviations from the normal values
in neurological examinations (data not shown).
Computed tomography (CT) of the head was then
performed. In its initial phase, CT imaging revealed
hyperdense foci, corresponding to massive calci  -
fications in the nuclei of the base of the brain, 
in the thalamus, as well as subcortical in the white
matter of both frontal lobes (Figure 2). Massive
calcifications are also visible in the nuclei and in the
AB
Figure 1. A. Abundant inflammatory infiltrations from lymphoid and plasmatic cells in portal-biliary spaces, necrosis
of hepatocytes on peripheral hepatic lobules (piecemeal necrosis type). B. Hyperplasia of connective-fibrous tissue
within portal spaces. Porto-portal bridges sporadically visible538 Arch Med Sci 3, June / 2011
white matter of both cerebellar hemispheres 
(Figure 3). The changes were symmetrically con  -
figured in both cerebral and cerebellar hemispheres. 
No foci of pathological strengthening were
identified during the second phase of CT imaging
after contrast administration (data not shown).
Laboratory studies revealed a considerable
decrease in the total serum calcium concentration
(corrected vs. albumin concentration) to 3.5 mg/dl
(normal: 8.8-10.4 mg/dl), together with a high
phosphorus concentration of 12.3 mg/dl (normal:
2.8-4.5 mg/dl) and a decreased parathormone
concentration of 5.78 pg/ml. Due to identified
calcium-phosphate metabolism disorders, the
patient was transferred to the Clinic of Endo  cri  no  -
logy and Metabolic Diseases.
The recurring oral candidosis and the primary
hypoparathyroidism prompted the diagnosis of 
APS-1. The third, main component of the syndrome
is primary adrenocortical failure; no symptoms of
adrenal cortex failure were found in the patient,
while electrolyte concentration values and
glycaemia were normal. Five weeks after withdrawal
of the suppressive glucocorticosteroid doses, an
adrenal cortex stimulation test with corticotrophin
(250 μg Synacthen administered intravenously) was
performed. Cortisol concentration at the 60th min
of the test was 11.9 μg/dl, indicating the presence
of primary adrenocortical failure. The autoim  -
munological basis for the occurrence of primary
adrenocortical failure was confirmed by the
increased titre of anti-adrenal cortex antibodies 
(1 : 20 vs. the normal value of 1 : 10).
The applied treatment was multidirectional, with
a concomitant focus on dietary education targeted
at reducing the volumes of consumed phosphates.
Further treatment was launched, including calcium
agents (CaCO3), and vitamin D, with doses selected
to maximally normalize the calcium-phosphate
metabolism parameters. The goal of the therapy
was to achieve calcium concentration in serum
oscillating around the lower normal limit. The
patient was informed about adrenocortical failure
and adrenocortical crisis prognostic symptoms.
Hydrocortisone substitution was launched,
emphasizing the importance of flexible dose
modifications, taking into account the concomitant
stress.
After 12 months of therapy, the patient currently
feels well and does not report any complaints. The
most recent laboratory tests returned the following
results: serum ALT 14 U/l, AST 18 U/l, total bilirubin
0.67 mg/dl, total calcium 7.8 mg/dl, and phosphorus
4.52 mg/dl.
Discussion
Autoimmune hepatitis (AIH) is a chronic,
progressive, necrotic-inflammatory process in the
liver of unknown aetiology. Advancing lesions of
hepatic parenchyma may lead to liver cirrhosis [6]
and even to acute liver failure [7]. Three types of
AIH have been described, based on immuno  -
serological findings. Here we have presented a case
of autoimmune hepatitis as the initial symptom of
APS-1. The diagnosis of autoimmune hepatitis was
made from the criteria of the International
Autoimmune Hepatitis Scoring System in Brighton,
and the International Autoimmune Hepatitis Group
[8, 9]. High ALT, AST, and γ-globulin activities were
found in blood serum, the presence of anti-nuclear
antibodies was confirmed, and features of
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Figure 2. Computed tomography imaging revealed
hyperdense foci, corresponding to massive
calcifications in the nuclei of the base of the brain,
in the thymuses, as well as subcortical in the white
matter of both frontal lobes
Figure 3. Massive calcifications were visible in the
nuclei and in the white matter of both cerebellar
hemispheresArch Med Sci 3, June / 2011 539
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inflammation and periportal fibrosis with
inflammatory infiltrations from lymphoid and
plasmatic cells were seen in the histopathology of
a collected liver biopsy.
The patient received typical anti-suppressive
treatment with steroids, completed by addition of
azathioprine [10]. While a reduction of amino  -
transferase activities was initially achieved, the
levels increased after 3 months. Only the unique
attack of tetany prompted the extension of the
diagnostic protocol.
Fungal infections (Candida) are a frequently
described clinical symptom of APS-1, affecting the
mucosal membranes of the oral cavity, the
oesophagus, and distal sections of the gastric tract,
as well as the skin and its appendages [11]. The
immune background for chronic candidosis is
a selective deficit of T lymphocytes and the
associated impaired response to the presence of
antigens. While it is true that the patient did report
recurring episodes of oral candidosis in her history,
experienced since early childhood, the infections
were slight and easily explained by the
administered therapy with anti-fungal agents, and
thus they did not arouse anxiety.
A previous report has described the case of an
untreated 10-year-old girl who exhibited APS-1
symptoms from the 3rd year of her life, including
chronic nail and oral candidosis and hypo  para  -
thyroidism [12]. At the 6th year of the child’s life,
skin xanthochromia occurred, which then spon  -
taneously regressed. Four years later, symptoms of
hepatic failure developed, and despite urgent liver
transplantation, the child died a few years after the
operation. Advanced hepatitis with massive
necrosis was the histopathological diagnosis made
after evaluation of a collected liver section.
Another report presents data from a 31-year
observational study of 68 patients with APS-1 [13].
Features of chronic hepatitis were identified in 12
of the patients, while in one patient diagnosed
autoimmune hepatitis was the first symptom of
APS-1. Acute hepatic failure was the direct cause of
death in two out of nine deceased patients.
Autoimmune hepatitis occurs in 15-18% of APS-1
patients, sometimes directly causing death.
In conclusion, when patients with autoimmune
hepatitis are unresponsive to standard immuno  -
suppressive treatment, concomitant hormone
metabolism disorders should be taken into consi  -
deration.
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